URGN vs. AKBA, SPPI, PBYI, RAPT, MRNS, MNKD, DAWN, ABCL, CALT, and MIRM
Should you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include Akebia Therapeutics (AKBA), Spectrum Pharmaceuticals (SPPI), Puma Biotechnology (PBYI), RAPT Therapeutics (RAPT), Marinus Pharmaceuticals (MRNS), MannKind (MNKD), Day One Biopharmaceuticals (DAWN), AbCellera Biologics (ABCL), Calliditas Therapeutics AB (publ) (CALT), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical preparations" industry.
Akebia Therapeutics (NASDAQ:AKBA) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, community ranking, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.
Akebia Therapeutics has higher revenue and earnings than UroGen Pharma. Akebia Therapeutics is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.
Akebia Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 346.43%. UroGen Pharma has a consensus target price of $46.00, suggesting a potential upside of 245.86%. Given UroGen Pharma's higher probable upside, research analysts clearly believe Akebia Therapeutics is more favorable than UroGen Pharma.
33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are owned by institutional investors. 4.1% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 11.1% of UroGen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Akebia Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.
Akebia Therapeutics received 56 more outperform votes than UroGen Pharma when rated by MarketBeat users. However, 73.29% of users gave UroGen Pharma an outperform vote while only 63.96% of users gave Akebia Therapeutics an outperform vote.
Akebia Therapeutics has a net margin of -22.99% compared to Akebia Therapeutics' net margin of -123.74%.
In the previous week, Akebia Therapeutics had 1 more articles in the media than UroGen Pharma. MarketBeat recorded 2 mentions for Akebia Therapeutics and 1 mentions for UroGen Pharma. Akebia Therapeutics' average media sentiment score of 1.87 beat UroGen Pharma's score of 1.71 indicating that UroGen Pharma is being referred to more favorably in the news media.
Summary
Akebia Therapeutics beats UroGen Pharma on 8 of the 15 factors compared between the two stocks.
Get UroGen Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
UroGen Pharma Competitors List
Related Companies and Tools
